Utility of CRP as a Prognostic Biomarker to Guide Lenzilumab Treatment in Patients With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Thorax
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial
Thorax 2023 Jun 01;78(6)606-616, Z Temesgen, CF Kelley, F Cerasoli, A Kilcoyne, D Chappell, C Durrant, O Ahmed, G Chappell, V Catterson, C Polk, A Badley, VC MarconiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.